Erly Pen Injection (Liraglutide) — GLP-1 Therapy for Type 2 Diabetes and Weight Management

Brand Name: Erly | Generic Name: Liraglutide | Manufacturer: Eris Lifesciences Ltd | Form: Prefilled Pen Injection 6mg/ml, 3ml

Erly Pen Injection contains Liraglutide, a GLP-1 (Glucagon-Like Peptide-1) receptor agonist used to manage Type 2 Diabetes Mellitus and support medically supervised weight loss. It contains the same active ingredient as Victoza and Saxenda — offering proven therapeutic results at a more accessible price.

How It Works

Erly stimulates insulin release from the pancreas when blood sugar is high, slows stomach emptying, reduces liver sugar production, and suppresses appetite — helping control blood sugar and support weight loss.

Uses

• Type 2 Diabetes management in adults and children above 10 years
• Reduces risk of heart attack and stroke in diabetic patients with cardiovascular disease
• Weight management in overweight or obese patients alongside diet and exercise

Dosage and Administration

Inject subcutaneously into the abdomen, thigh, or upper arm once daily at the same time each day, with or without food. Starting dose is typically 0.6mg per day, increased gradually by your doctor. Rotate injection sites with each use. Do not inject into a vein or muscle.

Storage :

Refrigerate before first use. After opening, store below 30°C for up to 2 weeks. Do not freeze.

Side Effects :

Common: nausea, vomiting, diarrhoea, decreased appetite, constipation, headache, fatigue, dizziness. Consult your doctor if side effects persist.

Warning :

Not recommended for patients with a personal or family history of thyroid tumors, pancreatitis, or diabetic ketoacidosis. Not for use in Type 1 Diabetes. Use under medical supervision only. Avoid alcohol during treatment.

Frequently Asked Questions (FAQs)

Q1. Is Erly Pen the same as Victoza or Saxenda? Yes. Erly contains Liraglutide — the same active ingredient in Victoza (for Type 2 Diabetes) and Saxenda (for weight management). It works through the same GLP-1 receptor agonist mechanism.

Q2. Can Erly Pen be used for weight loss without diabetes? Yes. Erly can be prescribed for weight management in overweight or obese patients alongside a reduced-calorie diet and exercise. Consult your doctor to confirm suitability.

Q3. How do I use the Erly Pen? Attach a new needle, choose your injection site, clean with an alcohol swab, pinch the skin, insert at 90 degrees, and press the button to inject. Dispose of the needle after each use.

Q4. What if I miss a dose? Inject as soon as you remember. If the next dose is within 72 hours, skip the missed dose and resume your regular schedule. Do not double the dose.

Q5. Is Erly safe during pregnancy? No. Erly is not recommended during pregnancy or breastfeeding. Consult your doctor for a safer alternative such as insulin.

Q6. Can I use Erly with other diabetes medications? Yes, but doses may need adjustment. Do not mix Erly with insulin in the same syringe and avoid concurrent use with other GLP-1 agents such as exenatide or lixisenatide.

References:

1. MedlinePlus — Liraglutide Drug Information: https://medlineplus.gov/druginfo/meds/a611003.html
2. Mayo Clinic — Liraglutide Subcutaneous Route: https://www.mayoclinic.org/drugs-supplements/liraglutide-subcutaneous-route/description/drg-20073828